You have 9 free searches left this month | for more free features.

JAK inhibitor

Showing 26 - 50 of 7,638

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Rheumatoid Arthritis, JAK Inhibitor, Musculoskeletal Ultrasound Trial in Nagasaki (upadacitinib 15mg/day)

Recruiting
  • Rheumatoid Arthritis
  • +3 more
  • upadacitinib 15mg/day
  • Nagasaki, Japan
    Nagasaki University Hospital
Nov 24, 2021

Chronic Hand Dermatitis Trial in Rochester (Ruxolitinib)

Recruiting
  • Chronic Hand Dermatitis
  • Rochester, New York
    UR Medicine Dermatology College Town
Aug 9, 2022

Hematopoietic and Lymphoid Cell Tumor, Steroid Refractory GVHD Trial in Houston (Cellular Therapy, Ruxolitinib)

Recruiting
  • Hematopoietic and Lymphoid Cell Neoplasm
  • Steroid Refractory Graft Versus Host Disease
  • Houston, Texas
    M D Anderson Cancer Center
Jul 9, 2022

Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, MDS Trial in Saint Louis (procedure, drug, other)

Recruiting
  • Acute Myelogenous Leukemia
  • +4 more
  • Stem cell transplantation
  • +3 more
  • Saint Louis, Missouri
    Washington University School of Medicine
Aug 23, 2022

Arthritis, Rheumatoid, Arthritis, Psoriatic, Spondyloarthritis Trial in Caba, Ciudad Autonoma Buenos Aires (DMARDs, biologic

Recruiting
  • Arthritis, Rheumatoid
  • +2 more
  • Caba, Buenos Aires, Argentina
  • +1 more
Mar 26, 2021

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute

Active, not recruiting
  • Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
  • +2 more
  • Columbus, Ohio
  • +2 more
Aug 10, 2022

Cicatricial Alopecia Trial in New York (PF-06651600)

Not yet recruiting
  • Cicatricial Alopecia
  • New York, New York
    Icahn School of Medicine at Mount Sinai
Sep 19, 2022

Advanced Hepatocellular Carcinoma Trial in London (Itacitinib (INCB039110))

Recruiting
  • Advanced Hepatocellular Carcinoma
  • Itacitinib (INCB039110)
  • London, United Kingdom
    Imperial College Healthcare NHS Trust
Jul 14, 2022

Vitiligo, Effect of Drug Trial (JAK-2 inhibitor, Topical corticosteroid)

Not yet recruiting
  • Vitiligo
  • Effect of Drug
  • JAK-2 inhibitor
  • Topical corticosteroid
  • (no location specified)
Mar 19, 2022

Bronchiolitis Obliterans Trial in Houston (Itacitinib, Itacitinib Adipate)

Recruiting
  • Bronchiolitis Obliterans
  • Houston, Texas
    M D Anderson Cancer Center
Jan 24, 2023

Myelofibrosis Trial in Worldwide (Imetelstat 4.7 mg/kg, Imetelstat 9.4 mg/kg)

Completed
  • Myelofibrosis
  • Imetelstat 4.7 mg/kg
  • Imetelstat 9.4 mg/kg
  • Birmingham, Alabama
  • +71 more
Aug 17, 2021

Arteritis, Giant Cell Trial in Rochester (Baricitinib)

Completed
  • Arteritis, Giant Cell
  • Rochester, Minnesota
    Mayo Clinic
Apr 7, 2022

Vitiligo, JAK Inhibitor Trial in Canada, United States (Ruxolitinib 1.5% cream, NB-UVB phototherapy)

Recruiting
  • Vitiligo
  • JAK Inhibitor
  • Ruxolitinib 1.5% cream
  • NB-UVB phototherapy
  • Fountain Valley, California
  • +13 more
Jul 6, 2022

Primary Myelofibrosis, Secondary Myelofibrosis Trial in Seattle (procedure, drug, radiation)

Recruiting
  • Primary Myelofibrosis
  • Secondary Myelofibrosis
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • +9 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jun 21, 2022

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Untreated Chronic Lymphocytic Leukemia Trial in Houston (Ruxolitinib,

Completed
  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  • Untreated Chronic Lymphocytic Leukemia
  • Houston, Texas
    M D Anderson Cancer Center
Mar 23, 2021

Myelofibrosis Trial in Belgium, Netherlands (Pacritinib)

Active, not recruiting
  • Myelofibrosis
  • Antwerpen, Belgium
  • +11 more
Aug 19, 2022

Metastatic Leiomyosarcoma, Metastatic Synovial Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma Trial in Seattle

Recruiting
  • Metastatic Leiomyosarcoma
  • +17 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Oct 13, 2022

Primary Myelofibrosis, Secondary Myelofibrosis Trial in Duarte (procedure, drug, other)

Active, not recruiting
  • Primary Myelofibrosis
  • Secondary Myelofibrosis
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • +9 more
  • Duarte, California
    City of Hope Medical Center
Nov 2, 2021

Myelomonocytic Leukemia Trial in United States (Ruxolitinib)

Completed
  • Myelomonocytic Leukemia
  • Tampa, Florida
  • +5 more
Sep 9, 2022

COVID19, COVID-19, COVID Trial in United States (Pacritinib, Placebo)

Terminated
  • COVID19
  • +2 more
  • Orange, California
  • +20 more
Sep 23, 2021

Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis Trial in Worldwide (KRT-232, TL-895)

Recruiting
  • Myelofibrosis
  • +3 more
  • Birmingham, Alabama
  • +36 more
May 5, 2022

Lupus or SLE, Nephritis Trial in Assiut (Baricitinib 4 MG, Baricitinib 2 MG, MMF)

Recruiting
  • Lupus or SLE
  • Nephritis
  • Baricitinib 4 MG
  • +2 more
  • Assiut, Yes, Egypt
    Manal Hassanien
Jan 13, 2023

Recurrent Classical Hodgkin Lymphoma Trial in Cologne (Ruxolitinib)

Completed
  • Recurrent Classical Hodgkin Lymphoma
  • Cologne, Germany
    1st Dept. of Medicine, Cologne University Hospital
Apr 3, 2020

Hemophagocytic Lymphohistiocytoses, Cytokine Storm Trial in Hangzhou (Dexamethasone, Etoposide, Ruxolitinib)

Not yet recruiting
  • Hemophagocytic Lymphohistiocytoses
  • Cytokine Storm
  • Hangzhou, Zhejiang, China
    The Children's Hospital of Zhejiang University School of Medicin
Aug 4, 2022

Rheumatoid Arthritis, Inflammatory Rheumatism, Psoriatic Arthritis Trial in France (no intervention)

Recruiting
  • Rheumatoid Arthritis
  • +3 more
  • no intervention
  • Antibes, France
  • +59 more
Oct 25, 2022